Effects of Biliopancreatic Diversion on Bone Turnover Markers and Association with Hormonal Factors in Patients with Severe Obesity.
Adiponectin
/ blood
Adult
Aged
Biliopancreatic Diversion
/ methods
Biomarkers
/ analysis
Bone Density
/ physiology
Bone Remodeling
/ physiology
Cohort Studies
Female
Hormones
/ analysis
Humans
Male
Middle Aged
Obesity, Morbid
/ blood
Osteocalcin
/ blood
Osteoprotegerin
/ blood
Weight Loss
/ physiology
Young Adult
Bariatric surgery
Biliopancreatic diversion
Biochemical markers of bone turnover
Bone mineral density
Hormones
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
pubmed:
28
11
2018
medline:
25
3
2020
entrez:
28
11
2018
Statut:
ppublish
Résumé
This study evaluated early and medium-term changes in bone turnover markers, and their associations with weight loss, total bone mineral density (BMD), and hormonal changes after biliopancreatic diversion (BPD). Ancillary study from a one-year prospective cohort of 16 individuals assessed before, 3 days, 3 and 12 months after BPD. Bone turnover markers (C-terminal telopeptide (CTX), intact osteocalcin (OC), sclerostin, and osteoprotegerin (OPG)) and several hormones were measured at each visit. Total BMD by DXA was assessed at baseline, 3 and 12 months after BPD. Three participants were lost to follow-up. CTX increased significantly at 3 days (+ 66%), 3 months (+ 219%), and 12 months (+ 295%). OC decreased at 3 days (- 19%) then increased at 3 months (+ 69%) and 12 months (+ 164%). Change in sclerostin was only significant between 3 days and 3 months (+ 13%), while change in OPG was significant between baseline and 3 days (+ 48%) and baseline and 12 months (+ 45%). CTX increase correlated negatively with weight loss at 3 (r = - 0.63, p = 0.009) and 12 months (r = - 0.58, p = 0.039), and total BMD decrease (r = - 0.67, p = 0.033) at 12 months. Change in insulin and adiponectin correlated with changes in bone turnover markers independently of weight loss. BPD causes an earlier and greater increase in bone resorption over bone formation markers and a decrease in total BMD. Sclerostin did not increase as expected following extensive weight loss. Changes in insulin and adiponectin seem to play a role in the activation of bone remodeling after BPD.
Sections du résumé
BACKGROUND
This study evaluated early and medium-term changes in bone turnover markers, and their associations with weight loss, total bone mineral density (BMD), and hormonal changes after biliopancreatic diversion (BPD).
METHODS
Ancillary study from a one-year prospective cohort of 16 individuals assessed before, 3 days, 3 and 12 months after BPD. Bone turnover markers (C-terminal telopeptide (CTX), intact osteocalcin (OC), sclerostin, and osteoprotegerin (OPG)) and several hormones were measured at each visit. Total BMD by DXA was assessed at baseline, 3 and 12 months after BPD. Three participants were lost to follow-up.
RESULTS
CTX increased significantly at 3 days (+ 66%), 3 months (+ 219%), and 12 months (+ 295%). OC decreased at 3 days (- 19%) then increased at 3 months (+ 69%) and 12 months (+ 164%). Change in sclerostin was only significant between 3 days and 3 months (+ 13%), while change in OPG was significant between baseline and 3 days (+ 48%) and baseline and 12 months (+ 45%). CTX increase correlated negatively with weight loss at 3 (r = - 0.63, p = 0.009) and 12 months (r = - 0.58, p = 0.039), and total BMD decrease (r = - 0.67, p = 0.033) at 12 months. Change in insulin and adiponectin correlated with changes in bone turnover markers independently of weight loss.
CONCLUSION
BPD causes an earlier and greater increase in bone resorption over bone formation markers and a decrease in total BMD. Sclerostin did not increase as expected following extensive weight loss. Changes in insulin and adiponectin seem to play a role in the activation of bone remodeling after BPD.
Identifiants
pubmed: 30478790
doi: 10.1007/s11695-018-3617-x
pii: 10.1007/s11695-018-3617-x
doi:
Substances chimiques
ADIPOQ protein, human
0
Adiponectin
0
Biomarkers
0
Hormones
0
Osteoprotegerin
0
TNFRSF11B protein, human
0
Osteocalcin
104982-03-8
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
990-998Subventions
Organisme : CIHR
ID : MOP 97947
Pays : Canada
Références
JBMR Plus. 2018 May 01;2(3):121-133
pubmed: 30283897
Exp Cell Res. 2005 Sep 10;309(1):99-109
pubmed: 15963981
Rev Endocr Metab Disord. 2014 Jun;15(2):149-56
pubmed: 24170312
Obes Surg. 2010 Nov;20(11):1524-9
pubmed: 20740379
Front Endocrinol (Lausanne). 2017 May 03;8:98
pubmed: 28515711
Cell. 2010 Jul 23;142(2):309-19
pubmed: 20655471
BMC Cell Biol. 2007 Nov 29;8:51
pubmed: 18047638
J Bone Miner Res. 2016 Jan;31(1):40-51
pubmed: 26332798
Diabetes. 2017 Nov;66(11):2743-2755
pubmed: 28835473
Int J Surg. 2014;12(9):976-82
pubmed: 25110331
Obes Surg. 2006 Nov;16(11):1425-32
pubmed: 17132406
Obesity (Silver Spring). 2011 Dec;19(12):2388-93
pubmed: 21617641
Cochrane Database Syst Rev. 2014 Aug 08;(8):CD003641
pubmed: 25105982
Z Rheumatol. 2014 May;73(4):342-8
pubmed: 24811358
J Bone Miner Res. 2012 May;27(5):1215-21
pubmed: 22392834
J Bone Miner Res. 2014 Jul;29(7):1507-18
pubmed: 24677277
J Periodontal Implant Sci. 2015 Jun;45(3):101-10
pubmed: 26131370
BMJ. 2016 Jul 27;354:i3794
pubmed: 27814663
Osteoporos Int. 2008 Jul;19(7):905-12
pubmed: 17924050
Toxicol Sci. 2000 May;55(1):171-88
pubmed: 10788572
J Clin Endocrinol Metab. 2014 Nov;99(11):E2325-9
pubmed: 25144635
Endocrine. 2016 Jul;53(1):313-21
pubmed: 26956843
Obes Surg. 2010 Apr;20(4):468-73
pubmed: 19937150
Lancet Diabetes Endocrinol. 2014 Feb;2(2):165-74
pubmed: 24622720
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1112-1121
pubmed: 28324004
Calcif Tissue Int. 2016 Jun;98(6):546-55
pubmed: 26749312
Nutr Res. 2014 Aug;34(8):707-13
pubmed: 25172380
J Clin Invest. 2014 Apr;124(4):1-13
pubmed: 24642469
J Gastrointest Surg. 2002 Sep-Oct;6(5):690-8
pubmed: 12399058
Bonekey Rep. 2014 Jan 08;3:481
pubmed: 24466412
Ann N Y Acad Sci. 2002 Jun;966:73-81
pubmed: 12114261
Osteoporos Int. 2014 Jan;25(1):151-8
pubmed: 23912559
J Clin Endocrinol Metab. 2015 Apr;100(4):1452-9
pubmed: 25646793
J Bone Miner Res. 2010 Sep;25(9):2078-88
pubmed: 20229598
J Clin Endocrinol Metab. 2016 Feb;101(2):714-22
pubmed: 26600045
Obes Facts. 2013;6(2):193-202
pubmed: 23615494
Obes Surg. 2017 Jul;27(7):1789-1796
pubmed: 28091892
Bone. 2018 Mar;108:98-105
pubmed: 29305997
J Clin Endocrinol Metab. 2013 Feb;98(2):541-9
pubmed: 23295461
J Clin Endocrinol Metab. 2014 Feb;99(2):491-7
pubmed: 24276463
Endocr Connect. 2015 Sep;4(3):155-62
pubmed: 26047829
Mol Metab. 2013 Apr 19;2(3):133-41
pubmed: 24049728
J Bone Miner Res. 2006 Oct;21(10):1648-56
pubmed: 16995820
Obesity (Silver Spring). 2014 Aug;22(8):1838-46
pubmed: 24760439
JAMA. 2004 Oct 13;292(14):1724-37
pubmed: 15479938
Obes Surg. 2010 Mar;20(3):363-8
pubmed: 20217956
Medicine (Baltimore). 2015 Dec;94(48):e2087
pubmed: 26632892
Peptides. 2016 Mar;77:28-37
pubmed: 26344355
J Clin Endocrinol Metab. 2010 Jan;95(1):159-66
pubmed: 19858320
J Clin Endocrinol Metab. 2015 Mar;100(3):891-901
pubmed: 25490275
Clin Endocrinol (Oxf). 2017 Apr;86(4):520-525
pubmed: 28090669
Obes Surg. 2009 Nov;19(11):1497-503
pubmed: 19727982
Obes Surg. 2018 Aug;28(8):2339-2352
pubmed: 29512038
Surg Obes Relat Dis. 2013 Jul-Aug;9(4):526-30
pubmed: 22498360
Trends Mol Med. 2009 Oct;15(10):468-77
pubmed: 19811952
J Bone Miner Res. 2011 Apr;26(4):677-80
pubmed: 21433069
Cell. 2010 Jul 23;142(2):296-308
pubmed: 20655470
N Engl J Med. 2012 Apr 26;366(17):1577-85
pubmed: 22449317